Bayer AG
Rating
Updated: Sep 14, 2026Why Price Moved
Shares are trading higher after Bayer sold its can...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
A detailed description of the company is not yet available.
Latest News
1 day ago · wsj.com
Bayer Sells Cancer Drug to Gruenenthal for Up to $431 MillionThe drug, approved to treat various forms of cancer, is due to lose patent protection in the EU in 2029 and in the U.S. a year later.
5 days ago · zacks.com
FDA Approves Label Expansion of BAYRY's Kidney Disease Drug KerendiaBayer's Kerendia gains FDA approval for CKD linked to type 1 diabetes, expanding its patient reach and growth prospects.
5 days ago · businesswire.com
Bayer's KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 DiabetesWHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA® (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline and end-stage kidney disease in adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D), following the agency's Priority Review of the supplemental New Drug Application (.
8 days ago · reuters.com
Bayer's Monsanto unit urges Missouri judge to approve $7.25 billion Roundup settlementBayer's Monsanto unit urged a Missouri judge on Monday to approve its $7.25 billion proposed settlement of lawsuits alleging that its weedkiller Roundup causes cancer, saying there is no other way to resolve the litigation that has weighed on the German company for years.
Add to Watchlist
Select watchlists to add or remove BAYRY